Skip to main content

Table 2 Relationship between Ezrin protein overexpression and clinicopathological features of gastric adenocarcinoma

From: Ezrin overexpression predicts the poor prognosis of gastric adenocarcinoma

Clinical features

No. of cases

Strongly positive cases (%)

P-value

Age

 <50

96

60 (62.5%)

NS

 51-69

181

92 (50.8%)

 ≥70

29

16 (55.2%)

Gender

  

NS

 Male

164

102 (62.2%)

 Female

113

66 (58.4%)

Lauren Types

  

<0.05, a

 Intestinal type

117

77 (65.8%)

 Diffuse type

139

85 (61.2%)

 Mixed type

21

6 (28.6%)

WHO’s Histological Types

  

NS

 Well-diff. ade.

85

42 (49.4%)

 Moderately-diff. ade.

103

54 (52.4%)

 Poorly-diff. ade.

59

50 (84.7%)

 Undifferentiated ade.

5

3 (60.0%)

 Signet ring cell carcinoma

9

5 (55.6%)

 Mucinous ade.

16

14 (87.5%)

LN Metastasis

  

<0.01

 Negative

151

53 (35.1%)

 Positive

126

115 (91.3%)

Clinical Stage

  

<0.05, b

 0

39

14 (35.9%)

 IA

47

12 (25.5%)

 IB

51

23 (45.1%)

 II

75

59 (78.7%)

 IIIA

59

54 (91.5%)

 IV

6

6 (100%)

Disease Free Survival

  

<0.01

 ≥3 years

152

53 (34.9%)

 

 <3 years

125

115 (92.0%)

 
  1. ade.: Adenocarcinoma; diff.: differentiated; NS: not significant. * Strongly positive: ++ and +++.
  2. a: Intestinal & Diffuse types vs Mixed type.
  3. b: Stage 0 + Stage IA + Stage IB vs Stage II + Stage IIIA + Stage IV.